17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01136213
(ClinicalTrials.gov)
April 201026/5/2010Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) StudyMorphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET StudyMultiple System AtrophyRadiation: PET (Positron Emission Tomography) Study;Other: Brain MRI (magnetic resonance imaging);Drug: Fluoxétine / PlaceboUniversity Hospital, BordeauxNULLCompleted30 Years80 YearsAll53N/AFrance
2NCT01146548
(ClinicalTrials.gov)
May 200816/6/2010Fluoxetine in Multiple System Atrophy PatientsAssessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized TrialMultiple System AtrophyDrug: FLUOXETINEUniversity Hospital, ToulouseClinical Research Center, ToulouseCompleted30 Years80 YearsBoth87Phase 2France
3EUCTR2007-004922-26-FR
(EUCTR)
12/02/200831/01/2008Evaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétineEvaluation de l’effet de la fluoxétine chez le patient atteint d’atrophie multi-systématisée : Etude randomisée en double-insu versus placebo. - Etude MSA-fluoxétine atrophie multisystématisée
MedDRA version: 9.1;Level: LLT;Classification code 10064060;Term: Multiple system atrophy
Trade Name: PROZACCHU ToulouseNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France